A MULTICENTER, OPEN-LABEL, DOSE-FINDING CLINICAL TRIAL TO ASSESS THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL EFFICACY OF RVU120 IN COMBINATION WITH VENETOCLAX IN PARTICIPANTS WITH ACUTE MYELOID LEUKEMIA WHO FAILED PRIOR THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT (RIVER-81)
- Registry ID
- RIVER-81
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- RYVU THERAPEUTICS S.A.
- Last update
- 2024-02-27
Conditions
Related clinical trials
- A RANDOMIZED PHASE II STUDY COMPARING
CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME,
CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND
(DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX IN PATIENTS AGED 59 OR
YOUNGER WHO ARE CONSIDERED HIGH-RISK (ADVERSE) ACUTE MYELOID LEUKEMIA AS
DETERMINED BY MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
- A GLOBAL MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 3 REGISTRATIONAL STUDY OF
OLVEREMBATINIB (HQP1351) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID
LEUKEMIA (POLARIS-2)
- A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS
CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK
ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL
- A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
- A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE ACTIVITY, SAFETY AND PHARMACOKINETICS OF LENALIDOMIDE (REVLIMID®) IN PEDIATRIC SUBJECTS FROM 1 TO <= 18 YEARS OF AGE WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
View on source registry